ITM is developing a proprietary portfolio and precision oncology pipeline of targeted treatments in various stages of clinical development, which address a broad range of cancers. By leveraging its nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life.
Each year, millions of people are diagnosed with cancer around the world. Although there has been a considerable improvement in therapeutic options against cancer, it still remains one of the major causes of death worldwide. BeiGene is dedicated to discovering, innovateing and developing better treatment against cancer to create a lasting impact on the patients with a mission to become global leader in oncology research.
Cancer is a major global public health problem and despite considerable advances in disease awareness, diagnosis and treatment, it remains an area of significant unmet medical need. Boehringer Ingelheim has a long-term commitment to deliver tomorrow’s cancer therapies by discovering and developing novel treatment options that combine ground-breaking science with high therapeutic value for patients.
|e-ESO (European School Oncology e-learning)
e-ESO is an online Medical Education resource provided by The European School of Oncology (ESO) for oncologists. Their CME and ESMO-MORA accredited e-sessions can be viewed live or recorded, and oncologists are invited to test their knowledge in the Mastermind quiz. Boehringer Ingelheim is delighted to support e-ESO with an unlimited Medical Education grant for their award-winning patient care software ePatCare®. Clinicians can create, view, share and present their clinical patient cases online. Check out the latest ESO patient cases here.
|CSCO (Chinese Society of Clinical Oncology)
The Chinese Society of Clinical Oncology (CSCO) is a public professional academic group that is voluntarily constituted by clinical oncology professionals, relevant enterprises and public institutions. CSCO is committed to developing Continuing Medical Education for clinical oncology, enhancing multi-discipline collaboration, encouraging multi-center research, promoting the standardization of tumour diagnosis and treatment, and furthering the development of clinical oncology, with the aim of benefiting patients suffering from cancer.
|LACOG (Latin American Cooperative Oncology Group)
Founded in 2008, LACOG is the first multinational cooperative group in Latin America exclusively dedicated to clinical and translational research in cancer. Based in Brazil, LACOG has 147 investigator members from 70 institutions across Latin America. It aims to build and foster a network of LA investigators in oncology; to develop, conduct and coordinate academic studies and clinical trials in the region; and to cooperate with other international academic institutions and networks, groups and the pharmaceutical/biotechnology industry to facilitate the conduct of clinical research.
|SEO (Sociedad Ecuatoriana de Oncología)
SEO brings together Ecuadorian medical professionals with an interest in diagnostic, therapeutic or research areas Oncology. They seek to develop the research and practice of oncology in Ecuador, and to educate oncologists through Continuous Medical Education, to contribute to improved patient care.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Afatinib is an irreversible ErbB Family Blocker approved in over 40 countries worldwide including the EU, US, Japan, Taiwan, Canada and Mexico. It is indicated for the treatment of patients with distinct types of Epidermal Growth Factor Receptor (EGFR) mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), a specific type of lung cancer. It is an oral, once daily targeted therapy.
Nintedanib is a triple angiokinase inhibitor which targets the three key receptors involved in angiogenesis and tumour growth. Nintedanib in combination with docetaxel is approved in the European Union (EU) for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
|Oncology on YouTube
This Oncology Channel features informative videos on lung, ovarian, head & neck and breast cancer to raise awareness and provide useful information on the latest research and development in these areas.
SpringerMedizin and infill healthcare communication collaborate to produce and distribute memo inOncology Special Issues to the medical community.
SpringerMedizin.at is a specialist publisher that helps physicians from various disciplines to stay up to date. The medical portal provides quick access to specialist content – from anywhere, at any time. The contents on SpringerMedizin.at, such as newsletters, video tutorials or topic pages, come from the magazines and books or from self-researched articles of the journalists of the Springer medicine publishing house. Publishers anticipate the issues that will shape the field in the future. Experts pass on their knowledge and skills – from practice and clinic to their colleagues. Editors report and comment on developments in science and research competently, vividly, legibly – and also in an entertaining way.
|infill healthcare communication
infill and SpringerMedizin collaborate to produce and distribute memo inOncology Special Issues to the medical community.
infill healthcare communication: an innovative team of digital, medical and communication experts who make your healthcare initiatives fly. Quality medical education and digital communication are at the heart of what infill delivers through a combination of expertise, experience, knowledge and technology, ensuring optimum solutions for healthcare companies.